唐旭东提醒，中医认为小儿"脾常不足"，儿童的胃肠功能本就弱，如果节日期间饮食过饱过杂，容易导 致食积。中医强调，儿童脾胃调理应遵循"三分治疗七分养"的原则，同时要根据年龄分层施治，以温 和、安全为要。如果出现积食，应立即暂停食用油腻食物、干果、甜食等，将主食换成汤类、粥类、烂 面条等易于消化的流质或半流质饮食；一岁以下婴幼儿可用腹部按摩、推拿等方法调理；两岁以上儿童 可加用食疗、贴敷等方法。 转自：贵州日报 春节期间饮食丰富多样、油腻食物和零食增加，会加重脾胃运化负担。中医认为，脾胃为气血生化之 源。如何预防脾胃病？中医专家为呵护脾胃健康支招。 中国中医科学院西苑医院脾胃病研究所所长唐旭东建议：缓慢进餐、先吃蔬菜；餐中注意搭配，例如吃 一口肥腻食物搭配几口清爽蔬菜；不宜大量喝酒或大量食用油炸干硬食物；注意食物的寒热平衡；餐后 可以散步、按摩腹部、冲泡消食茶饮等方式消食。 运动是调理脾胃的好方法。中国中医科学院广安门医院党委书记刘震说，八段锦总体上可以疏通经络、 调和气血、增强中气，其中，"调理脾胃须单举"一式能够促进脾胃消化功能，但运动宜以微汗为度，且 饭后不宜立即运动。 为防止过多油腻或偏咸食物伤及脾胃，北 ...

新华社北京2月12日电 题：长假将至，中医教你这样为脾胃"减负" 新华社记者田晓航 春节假期将至，饮食不规律叠加天气寒冷，容易引发消化不良、胃痛胃胀等节日病。如何运用中医药方 法促消化、健脾胃？2月12日，国家中医药管理局举行发布会，邀请中医专家为呵护脾胃健康支招。 中医认为，脾胃为气血生化之源。在脾胃病的预防和调护方面，中医药具有鲜明特色和独特优势。 国家中医药管理局中西医结合与少数民族医药司副司长欧阳波介绍，国家中医药局高度重视脾胃病防 治，遴选确定了53个脾胃病科作为国家中医优势专科，围绕中医优势病种制定并推广了14个脾胃病相关 中医诊疗方案，促进诊疗规范。 在中医看来，春节期间饮食丰富多样、油腻食物和零食增加，会加重脾胃运化负担。如何预防脾胃病？ 中国中医科学院西苑医院脾胃病研究所所长唐旭东建议：缓慢进餐、先吃蔬菜；餐中注意搭配，例如吃 一口肥腻食物搭配几口清爽蔬菜；不宜大量喝酒或大量食用油炸干硬食物；注意食物的寒热平衡；餐后 可以散步、按摩腹部、冲泡消食茶饮等方式消食。 运动是调理脾胃的好方法。中国中医科学院广安门医院党委书记刘震说，八段锦总体上可以疏通经络、 调和气血、增强中气，其中，"调理脾胃须 ...

Core Viewpoint - The traditional Chinese medicine industry is undergoing a significant transformation, where only companies that innovate while adhering to core principles will succeed [1] Company Strategy - Tai Long Pharmaceutical focuses on product innovation, supply chain management, channel cultivation, research and development, and brand culture to ensure product quality [1] - The company has established a multi-dimensional growth path centered around its flagship product, the Double Huanglian Oral Liquid, and aims to solidify its position as an "oral liquid expert" [2] Product Development - The Double Huanglian Oral Liquid has evolved into a product family that meets diverse consumer needs, including formulations for children, seniors, and those with specific health conditions [2] - Continuous technological upgrades and clinical trials are being conducted to enhance product quality and extend the product lifecycle [2][6] Market Position - Tai Long Pharmaceutical ranks among the top five in public medical institutions for cold medicine and maintains a strong presence in retail pharmacies [3] - The company is expanding its product line into other therapeutic areas, including cardiovascular and digestive health [3] Dual-Engine Growth - The company leverages traditional techniques alongside modern technology to enhance product quality and traceability, ensuring consumer trust [4] - Tai Long Pharmaceutical is actively participating in the "health and wellness" market, aiming for nationwide expansion through a combination of online and offline strategies [4] Research and Development - The subsidiary, New Leading Pharmaceutical, emphasizes technological innovation and has established a dual-track research strategy [5] - New Leading has developed proprietary technologies in complex formulations and maintains strong partnerships with major pharmaceutical companies [6] Supply Chain Management - Tai Long Pharmaceutical has built over 70 standardized cultivation bases across the country, ensuring a stable supply of high-quality raw materials [7] - The company’s comprehensive supply chain strategy allows it to maintain cost stability amid rising raw material prices [7] Industry Challenges - The traditional Chinese medicine industry is facing challenges such as rising costs, regulatory changes, and the need for innovation [7] - Companies must navigate cost management, quality standards, and innovation to thrive in the evolving market landscape [7] Investment Strategy - The company seeks strategic investors who share a long-term vision and can complement its capabilities, particularly in the health sector [8]

Core Viewpoint - The company does not produce "Ganmaoling Granules" and clarifies its product offerings related to flu prevention and treatment [2]. Product Offerings - The company’s subsidiaries produce the following products: - Ganmao Qingre Granules - Ganmao Kousou Granules - Ganmao Zhike Granules - Sangju Ganmao Granules - Children's Ganmao Granules [2]. Flu Prevention and Treatment Products - The company’s main products for flu prevention and treatment include: - Huoxiang Zhengqi Oral Liquid - Lingyang Ganmao Granules/Tablets - Qingre Jiedu Oral Liquid - Children's Ganmao Granules - Compound Banlan Gen Granules - Refined Yinqiao Jiedu Tablets - Vitamin C Yinqiao Tablets - Compound Acetaminophen and Amantadine Capsules - Ankang Huangmin Tablets - Phenacetin and Acetaminophen Tablets - Chlorpheniramine and Acetaminophen Tablets - Compound Acetaminophen Tablets - Sustained-release Ibuprofen Tablets - Acetaminophen and Phenobarbital Injection - Compound Licorice Oral Solution - Compound Licorice Tablets - Meiyu Pseudoephedrine Oral Solution - Children's Acetaminophen and Chlorpheniramine Granules - Children's Acetaminophen, Caffeine Tablets [2].

Core Viewpoint - Taiji Group (600129.SH) currently does not produce Ganmaoling granules, but offers a variety of other cold and flu-related products [1] Product Offerings - The company produces the following products: - Ganmao Qingre granules - Ganmao Kousou granules - Ganmao Zhike granules - Sangju Ganmao granules - Children's Ganmao granules [1] Flu Prevention and Treatment - The company's main products for flu prevention and treatment include: - Huoxiang Zhengqi oral liquid - Lingyang Ganmao granules/tablets - Qingre Jiedu oral liquid - Children's Ganmao granules - Compound Banlan Gen granules - Refined Yin Qiao Jiedu tablets - Vitamin C Yin Qiao tablets - Compound Acetaminophen and Amantadine capsules - Ankang Huangmin tablets - Phenacetin and Acetaminophen tablets - Chlorpheniramine and Acetaminophen tablets - Compound Paracetamol tablets - Ibuprofen sustained-release tablets - Acetaminophen and Phenobarbital injection - Compound Glycyrrhiza oral solution - Compound Glycyrrhiza tablets - Meiyu Weima oral solution - Children's Acetaminophen and Huangnamin granules - Children's Acetaminophen, caffeine tablets [1]

Core Insights - The article highlights the strategic transformation and international expansion of Taiji Group, showcasing its improved financial performance and operational efficiency [1][2][3]. Financial Performance - In the first three quarters of 2025, Taiji Group reported a revenue of 8.088 billion yuan and a net profit attributable to shareholders of 166 million yuan [2]. - The third quarter alone saw a revenue of 2.430 billion yuan, with a net profit of 27.108 million yuan, indicating a narrowing year-on-year revenue decline to 7.13% from 27.6% in the first half of the year [2]. - The operating cash flow for the first three quarters was 166 million yuan, matching the net profit, with a significant improvement in cash flow per share from -1.24 yuan to 0.3 yuan, a year-on-year increase of 124.34% [2][3]. Operational Efficiency - Taiji Group's inventory turnover rate averaged 2.80 times per year, and total asset turnover averaged 0.70 times per year, indicating strong operational efficiency [2]. - The company successfully reduced its total expenses to 1.888 billion yuan, with the expense ratio dropping by 30.37% year-on-year, reflecting effective cost management [3]. International Expansion - Taiji Group has successfully registered over 30 product specifications in more than 20 countries, obtaining nearly 100 overseas registration approvals [4]. - The flagship product, Huoxiang Zhengqi Oral Liquid, has played a pivotal role in the company's international strategy, gaining market access in regions like Macau and Canada [4][5]. Strategic Initiatives - The company is transitioning its Huoxiang Zhengqi product line from a seasonal remedy to a year-round health product, broadening its market appeal [5]. - Taiji Group is embracing digital transformation with the "AI Digital Taiji" initiative, focusing on data-driven decision-making and marketing innovations [7]. Market Positioning - The company has positioned its products to cater to younger consumers, integrating them into lifestyle choices, such as pairing with local cuisine [6]. - Taiji Group's commitment to ESG principles is highlighted by its inclusion in the "2025 ESG Action Report," showcasing its leadership in corporate social responsibility [7].

Group 1 - The article provides a comprehensive checklist for college freshmen to prepare for the new academic year, ensuring they have all necessary items for a smooth transition [1][13] - Essential documents such as admission letters, ID cards, and photos are highlighted as crucial for enrollment [4] - Recommendations for personal items include seasonal clothing, toiletries, and storage solutions to maintain organization in dorms [5][6] Group 2 - Academic supplies like notebooks, pens, and lamps are suggested to support study habits and late-night studying [6][9] - Health and wellness items, including basic medications and personal care products, are emphasized for student well-being [7][8] - Technology essentials such as smartphones, chargers, and power strips are recommended for connectivity and convenience [8][10]

Group 1 - The announcement by the National Medical Products Administration and other authorities regarding the compliance of traditional Chinese medicine (TCM) material production quality management standards is highlighted [2] - Taiji Group Chongqing Fuling Pharmaceutical Factory and Chongqing Traditional Chinese Medicine Slice Factory have conducted audits on their supplier, Zhalantun Tianli Agricultural and Sideline Products Purchase and Sale Co., Ltd., and found it compliant with GAP requirements [2] - A comprehensive evaluation of the TCM materials used by Taiji Group and Chongqing Traditional Chinese Medicine Slice Factory confirmed compliance with the "Traditional Chinese Medicine Material Production Quality Management Standards" [2] Group 2 - The compliance information table indicates that Taiji Group Chongqing Fuling Pharmaceutical Factory produces "Huo Xiang Zheng Qi Oral Liquid" and uses Zhalantun Tianli as a supplier for "Cang Zhu" material [3] - The planting base for "Cang Zhu" is located in Inner Mongolia, with an area of 5060 mu [3] - Chongqing Traditional Chinese Medicine Slice Factory is also involved in the production of "Cang Zhu" slices, confirming the compliance of their material sourcing [3]

Core Insights - Taiji Group, once a leading player in the traditional Chinese medicine industry, is facing unprecedented operational challenges, with a significant decline in revenue and profit margins in the first half of 2025 [1][2][4] Financial Performance - In the first half of 2025, Taiji Group reported revenue of 5.66 billion yuan, a year-on-year decrease of 27.63%, and a net profit attributable to shareholders of 139 million yuan, down 71.94% [2][6] - The company's net profit margin has deteriorated significantly, with a non-recurring net profit of 120 million yuan, reflecting a 74.52% decline compared to the previous year [2][6] - The decline in performance is attributed to policy impacts and ongoing inventory digestion of certain products, which has been consistent with previous years' explanations [2][4] Industry Context - The pharmaceutical industry is experiencing pressures from policies such as volume-based procurement and medical insurance cost control, but Taiji Group's revenue decline of 27.63% and nearly 70% drop in net profit exceeds the industry average [2][4] - The company's previous high-growth strategy, which relied on heavy inventory stocking, has backfired, leading to high social inventory levels that are now being liquidated [2][4] Product Performance - Taiji Group's main revenue sources are heavily reliant on its pharmaceutical industrial and commercial sectors, with key products like Huoxiang Zhengqi Oral Liquid and Jizhi Syrup facing significant sales declines [8][9] - In 2024, the pharmaceutical industrial sector's revenue fell by 32.25%, with a further decline of 44.03% in the first half of 2025, indicating severe pressure on core products [8][9] Strategic Challenges - The company had set an ambitious revenue target of 50 billion yuan for 2025, but with only 5.66 billion yuan achieved in the first half, meeting this target appears highly unlikely [10] - Taiji Group's high inventory levels and ineffective marketing strategies have been likened to "running with sandbags," continuously dragging down profits [4][5] Financial Pressures - Taiji Group has faced additional financial strain with the freezing of bank accounts totaling 62.92 million yuan, which represents 1.73% of the company's audited net assets [12][13] - The company is taking steps to address its financial situation by selling idle assets, including properties in Chongqing and Chengdu, to improve liquidity [13]

Group 1 - The "Labor Heat Prevention Festival" care action was implemented at Henan Angang Zhoukou Steel Co., Ltd. to provide support and resources for workers facing high temperatures [1][3] - The company is a key player in the transformation and upgrading of the steel industry in Henan Province, with a focus on high-end steel manufacturing [2] - The company has established supply points in various workshops to provide cooling resources such as chilled mung bean soup and watermelon to workers [2][5] Group 2 - Health education lectures were conducted to address the unique working conditions of steel workers, focusing on potential health risks and emergency response to heat-related illnesses [5] - The company has implemented a three-tier protection system consisting of material support, equipment maintenance, and emergency training to ensure worker safety [5] - The initiative aims to extend care actions to more grassroots levels and listen to the stories of laborers working in high-temperature conditions [5]